Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

This study found that among prostate cancer patients undergoing a biopsy, those with metabolic syndrome tended to have a lower Gleason score compared to those without the syndrome.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.

This study found that the detection rate of clinically insignificant prostate cancer increases with the number of repeat prostate biopsies in patients with persistently suspicious prostate cancer.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

This study found that one year of finasteride treatment significantly reduced PSA levels and prostate volume in men with elevated PSA and negative prior biopsy, potentially aiding prostate cancer diagnosis.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

This workshop review from the Australian Hair and Wool Research Society discusses findings in cutaneous biology and endocrinology but presents no new research results.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.

In this prospective cohort study, male pattern baldness was identified as an independent predictor of prostate cancer, while the 2D:4D finger ratio was not associated with the cancer risk.

This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.

This case report from the authors highlights a rare diagnosis of high-grade prostate cancer in a 35-year-old man, showing strong functional recovery and no detectable PSA one year after robotic-assisted radical prostatectomy despite the usual onset being significantly later in life.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This review summarizes NCCN guidelines for prostate cancer early detection, focusing on strategies to maximize detection of potentially curable cases while minimizing unnecessary procedures, but it reports no new clinical findings.

This study found that 1 mg/day of finasteride significantly reduced serum PSA concentrations in men with androgenic alopecia aged 40–60 over 48 weeks, suggesting implications for prostate-cancer screening in this population.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

Finasteride may help prevent prostate cancer.

More biopsy cores and MRI before biopsy can improve prostate cancer detection.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.